MoneyWorks4Me

Beta Drugs - Quaterly Results

23 Oct 2026 Evaluate
The revenue for the September 2026 quarter is pegged at Rs. 580.11 millions, about 6.48% up against Rs. 544.80 millions recorded during the year-ago period.The Net Profit of the company vaulted to 145.02% to Rs. 37.12  millions from Rs. 15.15 millions in the previous quarter.Operating profit for the quarter ended September 2026 rose to 82.52 millions as compared to 74.78 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 580.11 544.80 6.48 1138.37 1208.05 -5.77 2254.30 2202.00 2.38
Other Income 18.59 27.43 -32.23 37.26 57.18 -34.84 111.43 61.92 79.96
PBIDT 82.52 74.78 10.35 202.75 179.61 12.88 396.87 376.08 5.53
Interest 6.51 29.74 -78.11 22.52 57.62 -60.92 118.07 47.56 148.25
PBDT 76.01 45.04 68.76 180.23 121.99 47.74 278.80 282.82 -1.42
Depreciation 26.27 23.82 10.29 51.12 44.20 15.66 96.69 74.42 29.92
PBT 49.74 21.22 134.40 129.11 77.79 65.97 182.11 208.40 -12.62
TAX 12.62 6.07 107.91 32.66 20.31 60.81 38.77 54.08 -28.31
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 37.12 15.15 145.02 96.45 57.48 67.80 143.34 154.32 -7.12
Equity 111.21 100.95 10.16 111.21 100.95 10.16 101.37 100.95 0.42
PBIDTM(%) 14.22 13.73 3.63 17.81 14.87 19.79 17.61 17.08 3.08
Peers
Company Name CMP
Sun Pharma. Inds. 1743.00
Dr. Reddys Labs. 1224.50
Cipla 1337.00
Lupin 1925.00
Zydus Lifesciences 1127.85
View more..